Intrinsiqs

Is Outlook Therapeutics, Inc. overvalued?

Outlook Therapeutics, Inc. (OTLK) — key valuation metrics and fundamentals.

No verdict
Price
$0.62
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$116.1M
Dividend yield
0.0%
Return on equity
222.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares OTLK's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.